gaintherapeutics.com - GANX Forward Price-to-Revenue Multiple

Corporate emblem and logo of Gain Therapeutics, Inc. (GANX)

Gain Therapeutics, Inc. (GANX) develops drugs for the therapy of neurodegenerative pathologies, focusing on the Gaucher and Parkinson's disease markets. The forward P/S multiple provided by the GURU.Markets system demonstrates potential sales growth, while 653.80 reflects the most recent value of the metric. Gain Therapeutics, Inc. (GANX) diversifies risks by targeting proteins, and the implementation of AI platforms in R&D optimizes costs in the absence of commercial products.

GANX (gaintherapeutics.com) Price to Expected Revenue Ratio history from 07/04/2022 to 05/14/2024

GANX (Gain Therapeutics Inc.): analytical breakdowns and indicator data

Summary company analysis:gaintherapeutics.com GANX
Product sample of Gain Therapeutics

A conservative analysis of Gain Therapeutics, Inc. (GANX) requires benchmarking market value against expected cash flows to assess the premium paid for future growth. The market capitalization-to-projected revenue ratio, reflected via the forward P/S multiple, demonstrates the efficiency of a hybrid trial outsourcing model that maintains control over platforms, thereby minimizing operational risks and stabilizing the company's investment profile.

Competitors of Gain Therapeutics, Inc.

Forward P/S Multiple HCA (HCA Healthcare, Inc.)|Price to Expected Revenue Ratio THC (Tenet Healthcare)|FMS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio solventum.com|EHC: Forward P/S Multiple|UHS - Market Cap to Expected Sales Ratio|DVA (DaVita Corp) - Forward P/S Multiple|RDNT: Forward Price to Sales|Forward P/S Multiple OPCH|SGRY (surgerypartners.com) - Forward Price to Sales|Forward P/S Multiple PINC (Premier Inc)|National Vision - Price-to-Projected Revenue Ratio|PGNY - Price-to-Projected Revenue Ratio|ARDT - Forward P/S Multiple|SEM: Forward P/S Multiple|astranahealth.com (ASTH) - Forward P/S Multiple|MD (mednax.com) - Forward P/S Multiple|Forward P/S Multiple usph.com|Forward P/S Multiple PNTG|Market Cap to Expected Sales Ratio Organogenesis Holdings|Forward P/S Multiple NUTX (nutexhealth.com)|Auna SA (AUNA) - Market Cap to Future Revenue Ratio|SBC: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Jeuveau EOLS|CYH (Community Health Systems Inc) - Forward Price-to-Revenue Multiple|SKIN: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple MDWD|BTMD: Forward Price to Sales|Price-to-Projected Revenue Ratio The Joint Corporation (JYNT)|Forward P/S Multiple DocGo Inc (DCGO)|Forward Price to Sales P3 Health Partners, Inc.|Forward P/S Multiple EUDA Health Holdings Limited EUDA|baselmedical.com - Forward P/S Multiple|CLGN: Price-to-Projected Revenue Ratio|Cuprina Holdings (Cayman) Ltd. (CUPR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Concord Medical|AMS (American Shared Hospital Services Inc) - Forward P/S Multiple|MEDIROM Corp (MRM) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ALBT|Market Cap to Expected Sales Ratio DIH Holding|Forward P/S Multiple XAGE (carmellcosmetics.com)|NIVF: Market Cap to Projected Revenue|ATIP: Forward Price-to-Revenue Multiple|CareMax Medical Group - Price to Expected Revenue Ratio|Kindly MD (KDLY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue MODV|Price-to-Projected Revenue Ratio Novo Integrated Sciences Corp|Market Cap to Future Revenue Ratio SunLink Health Systems SSY|Price-to-Projected Revenue Ratio IMAC Corp (BACK)